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Objectives. This study investigated the hypothesis that aging
selectively impairs endothelium-dependent function, which may
be reversible by administration of L-arginine.
Background. An impaired response to acetylcholine with aging
has been demonstrated in humans. However, the mechanisms
underlying this impaired response of the coronary microvascula-
ture remain to be determined.
Methods. We infused the endothelium-independent vasodilators
papaverine and glyceryl trinitrate (GTN) and the endothelium-
dependent vasodilator acetylcholine (1, 3, 10 and 30 g/min) into the
left coronary artery of 34 patients (27 to 73 years old) with atypical
chest pain, negative exercise test results, completely normal ﬁndings
on coronary angiography and no coronary risk factors. Coronary
blood ﬂow was measured with an intracoronary Doppler catheter.
The papaverine and acetylcholine infusions were repeated in 14
patients (27 to 73 years old) after an intracoronary infusion of
L-arginine (160 mol/min for 20 min).
Results. There was a signiﬁcant negative correlation between
aging and the peak coronary blood ﬂow response evoked by
acetylcholine (r  0.73, p < 0.0001). However, there was no
correlation between aging and the peak coronary blood ﬂow
response to papaverine (r  0.04, p  0.82) and GTN (r 
0.24, p  0.17). The peak coronary blood ﬂow response evoked
by acetylcholine correlated signiﬁcantly with aging before
L-arginine infusion (r  0.87, p < 0.0001), but this negative
correlation was lost after L-arginine infusion (r  0.37, p 
0.19).
Conclusions. The results suggest that aging selectively impairs
endothelium-dependent coronary microvascular function and that
this impairment can be restored by administration of L-arginine,
a precursor of nitric oxide.
(J Am Coll Cardiol 1996;28:1796–804)
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It is now well recognized that the endothelium plays a major
role in modulating vascular tone by synthesizing and metabo-
lizing vasoactive substances (1), including an endothelium-
derived relaxing factor (EDRF) (2) that is released after
stimulation of muscarinic receptors on endothelial cells by
acetylcholine as well as by other agonists or physical stimuli
(3,4). Endothelial-derived relaxing factor is identical to nitric
oxide or very closely related to it (5,6). Evidence that
acetylcholine-induced vasodilation is mediated by EDRF in-
cludes the observation that methylene blue (an agent thought
to inactivate EDRF in part by generation of superoxide free
radicals) (7) and L-arginine analogues (which inhibit the
synthesis of nitric oxide) can block acetylcholine-induced va-
sodilation (8,9).
Animal (10,11) and human (12,13) studies have shown that
endothelial dysfunction may occur with risk factors for coro-
nary artery disease and precede the development of structur-
ally evident atherosclerosis. Recently, in vivo intravascular
ultrasound evidence that these changes may occur in structur-
ally normal vessels has also been reported (14). Because it
precedes clinically evident atherosclerotic changes, endothelial
dysfunction may be one of the important initiating mechanisms
for atherosclerosis (15,16). In addition, impaired EDRF re-
lease from dysfunctional endothelium may promote platelet
aggregation and platelet-induced contractions of vascular
smooth muscle, leading to vasospasm-mediated ischemic
events (17,18).
Age is a recognized risk factor for cardiovascular disease,
and senescence is associated with morphologic and functional
changes in the coronary microvasculature (19). Animal studies
(20,21) have shown that coronary ﬂow reserve and the
endothelium-dependent dilation of the resistance arteries de-
crease with aging. It has been recently suggested (22) that
endothelium-dependent dilation of the resistance coronary
arteries evoked by acetylcholine may be decreased with aging
in humans. However, the number of subjects studied in that
study was small, and the mechanism of the attenuated coronary
blood ﬂow response to acetylcholine was not explored.
The mechanisms underlying the age-associated reduction in
the ability of the coronary microvasculature to dilate in re-
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sponse to acetylcholine remain to be determined. Experimen-
tal studies (21,23) demonstrating thinning and loss of endothe-
lial cells in aged animals suggest an impaired production of
EDRF. In addition, advanced glycosylation end products,
which accumulate in the vascular subendothelium in aging,
have been experimentally shown (24) to quench nitric oxide
and mediate defective endothelium-dependent vasodilation.
Nitric oxide, which accounts for the biologic activity of EDRF,
is derived from the metabolism of L-arginine to citrulline; thus,
L-arginine represents a precursor for the synthesis of nitric
oxide and EDRF (25). Although sufﬁcient endogenous
L-arginine might be present in normal vessels, data from
experiments suggest that the availability of L-arginine is a
rate-limiting factor in the production of EDRF in hypercho-
lesterolemic animals (26). We hypothesized that aging selec-
tively impairs endothelium-dependent function and that this
impairment may be reversible by short-term administration of
L-arginine.
Methods
Study patients. The study included 34 patients (mean
[SD] age 50.4  14.3 years, range 27 to 73; 18 men, 16
women) with atypical chest pain, normal exercise test results
and completely normal coronary arteries on angiography,
without coronary spasm. The coronary angiograms of all
patients were reviewed before the study by two independent
observers, and only patients with completely normal coronary
arteries were included in the study. Patients with hyper-
tension (deﬁned as chronically elevated blood pressure
150/95 mm Hg), hypercholesterolemia (total cholesterol
5.5 mmol/liter), diabetes mellitus, valvular heart disease or
left ventricular hypertrophy as assessed by electrocardiography
and echocardiography were excluded from the study. Patients
taking antihypertensive or cholesterol-lowering therapy were
also excluded from the study. No patients had a history of
previous myocardial infarction, and none were taking
hormone-replacement therapy. Patients were considered
smokers (n  10) if they were current smokers or had stopped
smoking within 3 months of the study.
Catheterization protocol. Patients fasted overnight before
undergoing cardiac catheterization. All cardiac medications
had been stopped for 48 h. Patients were advised not to smoke
on the day of the test. Patients received premedication with
diazepam (10 mg), and coronary angiography was performed
by the Judkins technique through the right femoral artery in all
patients. The proximal left anterior descending coronary artery
(LAD) was centered for optimal viewing after the initial
angiograms had been obtained. To eliminate vasoactive effects
of the contrast medium, at least 10 min was allowed to elapse
before the coronary blood ﬂow study.
Heparin sodium (10,000 U) was then given intravenously. A
size 8F angioplasty guide catheter was positioned at the left
coronary ostium. Through this catheter, a 0.014-in. (0.035 cm)
guidewire was advanced into the distal part of the LAD. Using
a monorail technique, a size 3F 20-MHz Doppler-tipped
catheter (Schneider, U.K.) was then positioned in the proximal
segment of the LAD. The Doppler catheter was then con-
nected to a Millar velocimeter (model MDV-20, Millar Instru-
ments) to obtain phasic and mean coronary blood ﬂow velocity
signals, which were recorded on a Mingograf recorder
(Siemens-Elema, Sweden). Baseline mean rest and phasic
coronary blood ﬂow velocities were then recorded. This tech-
nique has been extensively validated and described in detail
elsewhere (27,28). The following infusions were then given in
random order: a bolus injection of 14 mg of papaverine, saline
infusion of 0.5 ml/min for 2 min and acetylcholine (0.5 ml/min)
at doses of 1, 3, 10 and 30 g/min for 2 min at each dose. A
200-g dose of glyceryl trinitrate (GTN) (50 g/ml) was
infused over a 1-min period at the end. We used a 14-mg dose
of papaverine in this study because we previously showed (29)
that this dose produces maximal hyperemia in all patients. At
least 5 min was allowed to elapse between infusions to allow
coronary diameter and coronary blood ﬂow velocity changes to
return to baseline levels. Coronary angiography of the LAD
was performed before and 2 min after the administration of
each agent. To test the reproducibility of the epicardial
responses and coronary blood ﬂow changes, the infusions of
papaverine and acetylcholine were repeated in six patients
after a control infusion of saline.
L-Arginine infusion. In 14 of the same patients (8 men, 6
women; mean age 52.4  19.3, range 27 to 73) an intracoro-
nary infusion of L-arginine (160 mol/min for 20 min) was
performed a minimum of 10 min after the ﬁrst infusions. The
intracoronary infusions of papaverine (14 mg) and acetylcho-
line (0.5 ml/min) at doses of 1, 3, 10 and 30 g/min for 2 min
at each dose were then repeated. The GTN infusion was not
repeated in these patients. Coronary blood ﬂow measurements
were performed before and after each infusion, as previously
described.
Quantitative measurements. Coronary angiograms were
recorded on 35-mm cineﬁlm (50 frames/s) with a cineangio-
graphic system (Siemens, Germany). Quantitative measure-
ments of the LAD diameter in diastole, 2 mm from the tip of
the Doppler catheter, were performed using digital electronic
callipers (Sandhill Scientiﬁc Inc.). This method has been used
previously to assess the diameter of coronary arteries and has
been described in detail elsewhere (29–31). In our laboratory,
with this method, we have reported minimal interobserver (r
0.90) and intraobserver (r  0.91) variability (30,31).
Ethical approval. The study was approved by the Hunting-
don Health Authority Ethical Committee. Written informed
consent was obtained from all patients before the study.
Abbreviations and Acronyms
EDRF  endothelium-derived relaxing factor
LAD  left anterior descending coronary artery
GTN  glyceryl trinitrate
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Coronary blood ﬂow calculations. Coronary blood ﬂow
velocity was recorded at rest and after each infusion. The
Doppler velocity recordings were corrected for changes in the
arterial cross-sectional area to provide an estimate of volumet-
ric ﬂow. Estimates of coronary blood ﬂow (Q) were made from
measurements of mean coronary ﬂow velocity (V) and vessel
cross-sectional area (CSA):
QV CSA.
Cross-sectional area was calculated by the following equation:
CSAr2,
where r coronary artery radius as determined by quantitative
analysis of the angiograms obtained in the preselected views.
To obtain an estimate of coronary blood ﬂow at rest (in
mm/min), the rest cross-sectional area of the coronary artery
(in cm2) was multiplied by the mean coronary blood ﬂow
velocity (in cm/s) and by 60 s. The increases in coronary blood
ﬂow were expressed as the percent increase from baseline.
Statistical analysis. Results are reported as mean value 
SD. Analysis of variance for repeated measures followed by the
Bonferroni multiple-comparison test was used for comparing
serial changes in arterial pressure, heart rate, arterial diameter
and coronary blood ﬂow. The relation between hemodynamic
variables and age was assessed by linear regression analysis. In
addition, the pattern of blood ﬂow response evoked by acetyl-
choline was determined by assessing the slope of the percent
increase in coronary blood ﬂow in response to acetylcholine
(y-axis) versus log of acetylcholine dose. For comparison of
unpaired data, the Mann-Whitney U test was used. Differences
were considered signiﬁcant at p  0.05.
Results
Patients. There was no signiﬁcant difference in patient
variables between the young group (50 years old) and the
older group (50 years old). A history of smoking, arterial
blood pressure and male gender had no effect on the epicardial
responses or changes in coronary blood ﬂow. There was no
signiﬁcant correlation between serum cholesterol levels (mean
5.0  0.4 mmol/liter) and maximal coronary blood ﬂow
response to papaverine (r  0.08, p  NS) and acetylcholine
(r  0.3, p  NS).
Systemic hemodynamic variables. There was no signiﬁcant
change in rest heart rate or systolic pressure as a result of
papaverine, GTN, acetylcholine and L-arginine infusions.
Changes in LAD diameter. There was no signiﬁcant corre-
lation between age and baseline vessel diameter (y  3.96 
0.014x, r  0.25, p  0.16). Intracoronary infusions of saline
did not change arterial diameter signiﬁcantly. Administration
of acetylcholine produced a biphasic response. The diameter
increased signiﬁcantly after infusion of acetylcholine at a dose
of 10 g/min (p  0.001) and decreased after a dose of
30 g/min (p  0.001). There was no signiﬁcant difference
between men and women.
There was a signiﬁcant correlation between age and percent
changes in the diameter evoked with acetylcholine at the
dosages of 1 g/min (r  0.71, p  0.0001), 3 g/min (r 
0.51, p  0.002) and 10 g/min (r  0.69, p  0.0001).
There was a similar trend at 30 g/min, but this did not reach
signiﬁcance (r  0.32, p  0.07). There was a signiﬁcant
correlation between the maximal percent diameter change
evoked by acetylcholine and age (r  0.70, p  0.0001) (Fig.
1).
Changes in coronary blood ﬂow (Table 1). The infusion of
saline did not alter coronary blood ﬂow signiﬁcantly. Acetyl-
choline infusions increased the calculated coronary blood ﬂow
in a dose-dependent manner. There was no signiﬁcant differ-
ence between men and women (peak response 382  173% vs.
426  141%). The peak increase in coronary blood ﬂow
response to acetylcholine correlated signiﬁcantly with age (r 
0.73, p 0.0001) (Fig. 2). However, there was no correlation
between age and peak increase in coronary blood ﬂow re-
sponses to papaverine (r  0.04, p  0.82) (Fig. 3) and GTN
(r  0.24, p  0.17) (Fig. 3). To assess the effect of aging on
endothelium-dependent control of coronary blood ﬂow, we
compared the peak percent coronary blood ﬂow response to
acetylcholine with that to papaverine in each patient. The ratio
decreased signiﬁcantly with age (r  0.67, p  0.0001) (Fig.
4). The slope of the blood ﬂow relation to acetylcholine also
correlated signiﬁcantly with age (r  0.57, p  0.0005).
There was no signiﬁcant correlation between the peak coro-
nary blood ﬂow response to papaverine and acetylcholine (r 
0.2, p  NS).
Reproducibility of coronary responses. The epicardial and
coronary blood ﬂow changes were assessed before and after a
control infusion of saline in six patients. There were no
signiﬁcant differences in the responses to papaverine and
acetylcholine between the ﬁrst and second dose responses,
indicating good reproducibility. Saline infusion itself had no
Figure 1. Scatterplot of correlation of age and maximal (percent of
control values) diameter response to acetylcholine.
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signiﬁcant effect on the epicardial and coronary blood ﬂow
responses.
Effects of L-arginine infusion on coronary blood ﬂow (Table
1) and LAD diameter. There was a signiﬁcant correlation
between age and peak percent ﬂow increase in response to
acetylcholine in the 14 patients before infusion of L-arginine
(r  0.87, p  0.0001) (Fig. 5). L-Arginine infusion itself did
not affect coronary blood ﬂow at rest. However, the signiﬁcant
correlation between age and peak percent ﬂow increase in
response to acetylcholine was lost after L-arginine infusion (r
0.37, p  0.19) (Fig. 5). There was no signiﬁcant correlation
between age and peak percent ﬂow increase in response to
papaverine in the 14 patients before (r  0.17, p  NS) and or
after L-arginine infusion (r  0.26, p  NS). The effect of
L-arginine infusion on the peak percent ﬂow increase in
response to papaverine and acetylcholine is shown in Figure 6.
The effect of L-arginine on LAD diameter responses to
acetylcholine was less clear. At 1 g/ml of acetylcholine, the
signiﬁcant correlation with age and percent change in diameter
persisted after L-arginine infusion (r  0.72, p  0.003). At
3 g/ml, the negative correlation was lost after L-arginine
infusion (r  0.34, p  0.23). At 10 g/ml, however, the
signiﬁcant correlation persisted after L-arginine infusion (r 
0.72, p  0.004).
Comparison of younger (<50 years) and older age (>50
years). The age-related difference in response to L-arginine
(Fig. 5) was necessarily concentrated at both ends. We also
analyzed the L-arginine portion of the study by classifying the
patients into two groups (50 and 50 years old) by analysis
of variance. There was no signiﬁcant difference in rest coronary
blood ﬂow between the two groups or in the peak coronary
blood ﬂow response to papaverine. However, the response to
Table 1. Coronary Blood Flow Response to Acetylcholine, Papaverine and Glyceryl Trinitrate
Age
(yr)
Peak Papaverine
CBF Response*
Peak GTN
CBF Response*
Peak Ach
CBF
Response*
Peak Ach
CBF
Response
After
L-Arginine*
Standard
CBF
Response†
Slope of Ach
Dose–Flow Relation
(%log [g/min])
52 445 173 484 109 445
64 468 150 369 79 287
53 503 201 389 77 195
53 508 144 358 71 248
48 425 238 327 77 25
53 480 247 665 138 649
58 382 235 537 141 521
67 330 135 292 511 89 234
44 410 154 296 72 246
53 394 91 361 92 268
52 355 288 334 94 164
60 358 115 318 89 245
55 377 229 357 95 193
54 298 263 247 706 83 218
48 438 211 426 97 397
62 395 278 375 95 245
49 425 393 358 84 256
27 370 341 476 508 126 330
31 494 308 613 124 429
33 498 310 622 125 473
34 395 383 448 113 264
36 641 308 671 105 487
31 581 320 536 536 91 359
29 454 291 348 348 77 182
34 519 385 499 499 96 346
41 642 468 679 106 381
31 536 440 628 656 117 490
38 516 472 577 613 112 390
69 546 339 182 335 33 96
72 435 320 125 306 29 7
68 617 394 146 469 24 99
70 556 389 191 555 34 25
71 602 343 202 408 34 114
73 580 395 255 421 44 88
*Percent of control values. †Percent of acetylcholine (Ach)/papaverine. CBF coronary blood ﬂow; GTN glyceryl
trinitrate.
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acetylcholine was signiﬁcantly lower in the older group. This
difference was abolished after L-arginine infusion (Fig. 7). The
acetylcholine response of the younger group was not affected
signiﬁcantly by L-arginine infusion.
Discussion
The present study demonstrates that the coronary blood
ﬂow response to acetylcholine (an endothelium-dependent
vasodilator) decreased signiﬁcantly with aging, whereas that in
response to papaverine and GTN (endothelium-independent
vasodilators) was unaffected by aging. These data provide in
vivo evidence for isolated endothelial dysfunction with aging in
the absence of other risk factors for coronary artery disease.
This selective endothelial dysfunction was attenuated by intra-
coronary administration of L-arginine, the precursor of nitric
oxide, providing evidence that L-arginine can restore the
endothelial function of the coronary microcirculation in older
subjects.
Figure 2. Scatterplot of correlation of age and peak (percent of
control values) coronary blood ﬂow response to acetylcholine.
Figure 3. Scatterplot of correlation of age and peak (percent of
control values) coronary blood ﬂow response to papaverine (open
squares [r  0.04, p  0.82]) and GTN (solid squares [r  0.24,
p  0.17]).
Figure 4. Scatterplot of correlation of age and endothelium-dependent
increase in coronary blood ﬂow (percent of coronary blood ﬂow response
to acetylcholine vs. papaverine).
Figure 5. Scatterplot of correlation of age and peak (percent of
control values) coronary blood ﬂow response to acetylcholine before
(solid squares [y  612.48  2.3212x, r  0.38, p  0.18]) and after
infusion of L-arginine (open squares [y 746.37 7.8273x, r0.87,
p  0.0001]). Coincidental data points are not shown.
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Epicardial responses. There was diminished vasodilation
of the large epicardial coronary arteries in response to acetyl-
choline with aging. The vasomotor responses of the epicardial
coronary response to the low dosage (1, 3 and 10 g/min)
correlated inversely with aging, but the response to the high
dose (30 g/min) of acetylcholine did not, although there was
a trend toward negative correlation, similar to ﬁndings of
previous studies (12,22). The diminished vasodilation of the
epicardial coronary arteries in response to acetylcholine with
age may be caused by an effect of aging in the epicardial vessels
or by secondary effects due to less ﬂow-mediated vasodilation
of the epicardial vessels (32,33). Acetylcholine can paradoxi-
cally cause vasoconstriction by stimulation of speciﬁc musca-
rinic receptors located on the smooth muscle cells. Lack of
correlation between age and response to the high dose of
acetylcholine may thus be due in part to a direct vasoconstrict-
ing effect by the high dose, resulting in blunted endothelium-
dependent vasodilator response. However, there was no evi-
dence to suggest that the vasoconstriction associated with the
high dose of acetylcholine was any greater in older subjects.
Egashira et al. (22) have reported a signiﬁcant inverse
correlation between age and baseline diameter of epicardial
vessels. They concluded that this inverse correlation may
suggest the presence of certain structural changes in the
coronary artery wall (early atherosclerosis), as shown by patho-
logic and echocardiographic studies (34,35) because athero-
sclerosis is an age-related phenomenon. However, we did not
ﬁnd a signiﬁcant inverse correlation between the age and
baseline diameter of the epicardial vessels in our study.
Changes in coronary blood ﬂow. As in other studies
(22,36,37), intracoronary administration of acetylcholine pro-
gressively increased coronary blood ﬂow in our patients. This
endothelium-dependent increase in coronary blood ﬂow
evoked by acetylcholine was signiﬁcantly and inversely corre-
lated with aging. The maximal blood ﬂow response, the slope
of the ﬂow response to acetylcholine and the percent coronary
blood ﬂow response to acetylcholine compared with the re-
sponse to papaverine (i.e., endothelium-dependent vasodila-
tory reserve) all inversely correlated with aging. These ﬁndings
thus provide further in vivo evidence of an impaired
endothelium-dependent vasodilation of resistance coronary
arteries with increasing age in the present (and to our knowl-
edge, the largest) study reported to date. These clinical obser-
vations are consistent with ﬁndings in experimental models
that endothelium-dependent vasodilation in resistance arteries
decreases with age (21) and are similar to previous observa-
tions in smaller studies in humans (22,38).
Endothelial dysfunction was attenuated by intracoronary
administration of L-arginine, the precursor of nitric oxide,
providing evidence that L-arginine can restore the endothelial
function of the coronary microcirculation. Although beneﬁcial
effects of L-arginine have been reported for several cardiovas-
cular disorders associated with endothelial dysfunction, such as
hypercholesterolemia (39,40), posttransplant coronary occlu-
sive disease (41) and reperfusion (42), we believe that ours is
the ﬁrst study to demonstrate that endothelium-dependent
dysfunction of the coronary microvasculature associated with
aging can be attenuated or reversed by exogenous L-arginine
administration. Experimental studies (43,44) have documented
that L-arginine stereospeciﬁcally improves endothelium-
dependent relaxation. Taken together, these observations sug-
gest that endothelial dysfunction as deﬁned by the response to
acetylcholine is associated with a reversible reduction of
EDRF availability that can be overcome by L-arginine supple-
mentation. If so, supplementation of L-arginine could repre-
sent a novel therapeutic strategy to maintain normal endothe-
lial function in older subjects, thus perhaps preventing the
development or progression of atherosclerosis and reducing
Figure 6. Effect of L-arginine infusion on peak percent coronary blood
ﬂow (CBF) increase in response to papaverine and acetylcholine. *p
0.01, acetylcholine response before (solid bars) versus after (hatched
bars) L-arginine infusion.
Figure 7. Comparison of younger (50 years) and older (50 years)
age on peak coronary blood ﬂow (CBF) response (percent of control
values). The response to acetylcholine was signiﬁcantly lower in the
older group (*p  0.01) than the younger group. However, this
difference was abolished after L-arginine infusion. Symbols as in
Figure 6.
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the incidence of ischemic coronary events. In this context,
Cooke et al. (39) found that long-term dietary L-arginine
treatment not only improved endothelial function in hypercho-
lesterolemic rabbits, but, more important, attenuated the
development of atherosclerosis.
Gender-related differences in endothelial function in nor-
mal and hypercholesterolemic subjects have been reported
previously (45), with preservation of endothelial function in
premenopausal hypercholesterolemic women. However, there
was no gender difference observed in our study in the coronary
ﬂow responses evoked by acetylcholine, GTN or papaverine.
Because we investigated only patients with completely “nor-
mal” coronary arteries and the absence of known coronary risk
factors (e.g., hypertension, hypercholesterolemia), our data
would suggest that the selective endothelial dysfunction asso-
ciated with aging in the absence of coronary risk factors is not
inﬂuenced by gender.
Smoking, epicardial and coronary blood ﬂow responses.
We found that a history of smoking did not inﬂuence epicardial
responses or changes in coronary blood ﬂow, which is in
contrast to some previous reports. Although the short-term
effects of smoking appear to be consistent with a reduced
hyperemic response (46) and a decreased coronary artery
diameter (47), the long-term effects of smoking are less clear.
Zeiher et al. (48) noted that the ﬂow-dependent dilation
response was reduced in smokers (who had not smoked for at
least 4 h). Furthermore, Nitenberg et al. (49) noted that
coronary artery diameter did not change with 108 and 107
mol/liter acetylcholine infusions in smokers, whereas in non-
smokers there was progressive dilation. In contrast, Vita et al.
(12), demonstrated no association between smoking and en-
dothelial vasodilatory dysfunction. Similarly, Czernin et al. (46)
noted no change in hyperemic blood ﬂow in smokers compared
with nonsmokers. Egashira et al. (50) reported that by univar-
iate analysis only hypertension, hypercholesterolemia, age50
years and total number of coronary risk factors were associated
with impaired coronary blood ﬂow response to acetylcholine.
The possibility exists that some of the differences noted
between the studies may relate to times of last cigarette
smoked before the study, number of cigarettes smoked daily
and differences in patient groups (e.g., patients with minor
atherosclerotic coronary disease compared with normal coro-
nary arteries).
Possible mechanisms. The mechanisms of the attenuated
coronary blood ﬂow response to acetylcholine are open to
speculation and may involve age-related decreases in release of
EDRF-dependent relaxing factors, inactivation of EDRF or
the concomitant release of constricting factors by microvascu-
lar endothelial cells. It has recently been demonstrated (51)
that impaired endothelium-dependent vasodilation of coro-
nary microvessels in atherosclerotic animals was restored by
administration of L-arginine, suggesting the important role of
EDRF in the control of coronary blood ﬂow in atherosclerosis.
In healthy blood vessels, the prevailing concentrations of
L-arginine do not limit the rate of synthesis of EDRF. How-
ever, administration of L-arginine to hypercholesterolemic
rabbits can restore endothelium-dependent relaxation of hind-
limb resistance vessels (43) and the thoracic aorta (40).
L-Arginine can also restore acetylcholine-induced vasodilation
of epicardial coronary arteries in patients with atherosclerosis
and hypercholesterolemia (40). The implication of these ﬁnd-
ings with regard to the mechanisms of impaired endothelium-
dependent relaxation in atherosclerosis remains uncertain
because depletion of L-arginine in these conditions has not yet
been demonstrated.
Endothelial cells are known to transport L-arginine against
a concentration gradient using a carrier sensitive to inhibition
by NG-monomethyl-L-arginine. Bradykinin and adenosine
triphosphate stimulate L-arginine uptake, suggesting that nitric
oxide generation or formation of second messengers, such as
cyclic guanosine monophosphate, or both, may be involved in
stimulation of L-arginine uptake (52). It is unlikely that the
L-arginine infusion ameliorates any abnormalities in the trans-
duction pathways within the endothelial cells, leading to in-
creased uptake of L-arginine. One possible mechanism may be
that there is reduced afﬁnity of the L-arginine transporter upon
agonist stimulation with aging or, alternatively, there is reduced
nitric oxide generation or second-messenger levels locally with
aging. It is also possible that as nitric oxide synthase is compart-
mentalized within the cytoplasm, there may be a “relative deﬁ-
ciency” of L-arginine substrate in older patients (52). It is well
recognized that there is basal release of nitric oxide from
endothelial cells and suppression of L-arginine uptake, and an
accelerated degradation of L-arginine does not appear to occur
in nonstimulated cells. It is therefore unlikely that there may
be accelerated degradation of L-arginine with aging. However,
there may be increased EDRF degradation (e.g., by increased
levels of superoxide anions with aging) similar to the phenom-
ena observed with cigarette smoke (53) and hypercholesterol-
emia (54).
Clinical implications. Impaired endothelial function with
aging may result in adverse clinical events as a consequence of
alterations in the interaction of the vessel wall with platelets,
neutrophils and macrophages. Such changes may contribute to
the atherogenic process and the stability of atherosclerotic
plaques. Endothelial dysfunction of the coronary microcircu-
lation may modify the regulation of myocardial perfusion by
neurohumoral agents as well as facilitate small-vessel platelet
aggregation because it depresses the inhibitory effects of
EDRF on platelet adhesion and aggregation (55). Endothelial
dysfunction of the coronary microcirculation may thus predis-
pose to intermittent myocardial ischemia by restricting coro-
nary perfusion (e.g., by aggregates of activated platelets) and
may partly account for the much higher incidence of ischemic
coronary events observed in the elderly. Endothelium is also
likely to have a local effect on vessel wall stiffness and
compliance by the local release of vasodilators, such as nitric
oxide and prostacyclin. Endothelial dysfunction may thus be a
relevant factor in vessel wall remodeling in the presence of
atherosclerotic plaque. Glagov et al. (34) have demonstrated
that the same extent of atherosclerotic plaque in different
1802 CHAUHAN ET AL. JACC Vol. 28, No. 7
AGING AND ENDOTHELIAL DYSFUNCTION December 1996:1796–804
vessels has varying effects on lumen size because of differing
degrees of vessel wall remodeling or dilation.
Limitations of the study. We cannot exclude the possibility
that older subjects had early atherosclerosis that was not
evident angiographically because we did not perform intravas-
cular ultrasound studies. However, it is of note that the
epicardial responses evoked by acetylcholine infusions demon-
strated a biphasic response with predominant vasodilation, as
has previously been described in truly normal vessels (14,15),
whereas acetylcholine predominantly causes vasoconstriction
in atherosclerotic vessels (13,56).
We did not measure basal plasma levels of L-arginine in our
patients and therefore cannot rule out the possibility that the
levels were lower in the older group. However, such a differ-
ence has not been reported previously, and even in conditions
where L-arginine infusion has been shown to restore
acetylcholine-induced vasodilation (39,40,43), depletion of
L-arginine has not been demonstrated.
It is possible that L-arginine increased blood ﬂow by a
mechanism not related to nitric oxide synthesis. L-Arginine
administration is known to induce the release of insulin by a
physiochemical effect on the pancreatic islet cells (57). An
increase in serum insulin levels may potentially increase coro-
nary blood ﬂow similar to the limb vasodilation seen during
intraarterial insulin infusion in humans (58). However, it has
been shown in previous studies (43,59) that despite a similar
increase in serum insulin concentration with both L-arginine
and D-arginine, endothelium-dependent vasodilation was only
potentiated by L-arginine, indicating that increased insulin
release was unlikely to account for the increase in blood ﬂow.
It is possible that the observed phenomenon is due to
alterations in muscarinic receptors or postreceptor coupling
mechanisms, or both. Impairment of EDRF synthesis can be
proved only if nonreceptor-mediated endothelium-dependent
relaxation is also suppressed (e.g., as evoked by the calcium
ionophore A23187). We did not explore such a mechanism in
our study.
The ﬁnding that administration of L-arginine normalizes the
impaired coronary blood ﬂow responses evoked by acetylcho-
line with aging supports the existence of an acetylcholine-
stimulated L-arginine–nitric oxide pathway as an important
mediator of acetylcholine-induced vasodilation in the intact
human coronary circulation. However, our study did not allow
us to differentiate the potential mechanisms underlying this
endothelial dysfunction. In addition to the possibility of abnor-
mal production or destruction of EDRF, a concomitant release
of a constricting factor (60) that may be contributory cannot be
ruled out. In addition, functional alterations in the ﬂow-
induced activation of endothelial potassium channels that may
modify the response to acetylcholine also cannot be excluded
(61).
Conclusions. The results of our study suggest that there is
a selective impairment of endothelium-dependent vasodilation
with aging. We also showed that this selective endothelial
dysfunction may be attenuated by intracoronary administration
of L-arginine, the precursor of nitric oxide.
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